In the highly regulated pharmaceutical industry, implementing the latest technologies to help bring medical breakthroughs to market is of critical importance. That is why Wolters Kluwer Health has col...
Custom-built, medical research workflows advance pharma discovery
WALTHAM, Mass.: In the highly regulated pharmaceutical industry, implementing the latest technologies to help bring medical breakthroughs to market is of critical importance. That is why Wolters Kluwer Health has collaborated with some of the leading pharmaceutical companies to bring intuitive and easy-to-use workflows to the Ovid® research platform.
Scaling up customizable solutions
The pharma and biotech industries rely on obtaining the latest, most comprehensive clinical information to effectively do their jobs. Automation and efficiency are imperative to manage the massive volumes of information within regulatory, clinical writing, medical affairs, pharmacovigilance, health economics and outcomes research, or publications groups. This allows different organizational functions to complete key tasks with speed and accuracy, such as leveraging hard-to-find data to generate study designs, substantiating findings for regulatory agencies, and gathering the latest information regarding disease management.
“Each pharmaceutical, life sciences and biomedical organization must adhere to strict regulatory guidelines, while also having unique needs for their specific business focus. Providing those institutions with an expert solution that is flexible, while continuously supplying authoritative information in a timely and digestible manner, is crucial,” said Rafael Sidi, Senior Vice President & General Manager of Health Research, Wolters Kluwer Health. “The Ovid research platform is uniquely positioned to support this industry, empowering researchers by putting essential information from a vast array of trusted resources at their fingertips.”
Improving workflow and productivity through understanding researchers’ tasks
Ovid medical research solutions enhance search precision and workflow speed to maximize research productivity. Teams improve their efficiency with more focused results, drug-specific keywording, and a clear path to the full text of relevant research. Additionally, the platform helps reduce administrative overhead, by freeing team members to spend more time on stakeholder engagement and regulatory requirements.
Wolters Kluwer worked with the world’s top pharmaceutical company to develop new enhancements in the Ovid research platform that will improve research automation and efficiency across the industry. New research tool updates include:
Learn more about the vital role that the Ovid research platform can play for pharma organizations and review this case study on how an international, rare drug manufacturer is currently leveraging the platform’s tools to accelerate their research.
For more information about Wolters Kluwer, please visit: www.wolterskluwer.com
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.
Fonte: Business Wire
Scheduled for October, the world's largest startup event will bring together more than 2,000 exhibitors in Dubai, UAE
The Italian IoT company is in the US for the second phase of CALL4INNOVIT
The Italian company partners with MainStreaming for high-performance, energy-efficient video streaming
Software vendors developing vertical solutions against specific attack vectors are 'cool' again. And when it comes to email security, all companies now…
The "New Zealand Buy Now Pay Later Business and Investment Opportunities Databook - Q2 2024 Update" report has been added to ResearchAndMarkets.com's…
The "Kenya Buy Now Pay Later Business and Investment Opportunities Databook - 75+ KPIs on BNPL Market Size, End-Use Sectors, Market Share, Product Analysis,…
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”) will host two live webcasts on September 5, 2024.…
RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property solutions, announces that Mark Lawyer has joined…